Sunday, March 05, 2017 10:57:39 AM
Simply put - the share structure.
I believe it's in my sticky.
Neurotrope has had insider funding and is insider controlled through a few "wealth management" funds.
Just as high institutional ownership allows institutions and hedge funds like BlackRock to whipsaw a stock to shake out retail, high insider control has the ability to do the same.
Anavex has an active long term retail share base and institutions are having trouble shaking them out with volatility to get cheap positions. They have also offered stockholders an anti-takeover poison pill that retail actually participates in, it will be voted on at the next shareholder meeting.
Dollar per dollar, I believe that even if both drugs are successful my rights as a shareholder are safer when invested in Anavex and I have a greater chance of benefiting financially from the success of the company.
Beyond that, direct stimulation of synapse growth with a growth factor does not seem like a practical long term treatment. If I fertilize my plants too much they die. Maintenance of cellular homeostasis as in Anavex 2-73 seems like a more reasonable long term treatment goal. It is possible that the Neurotrope drug could be used to "jump start" severe cases but I do not see it as a widely used prophylactic drug which is likely for 2-73.
I believe it's in my sticky.
Neurotrope has had insider funding and is insider controlled through a few "wealth management" funds.
Just as high institutional ownership allows institutions and hedge funds like BlackRock to whipsaw a stock to shake out retail, high insider control has the ability to do the same.
Anavex has an active long term retail share base and institutions are having trouble shaking them out with volatility to get cheap positions. They have also offered stockholders an anti-takeover poison pill that retail actually participates in, it will be voted on at the next shareholder meeting.
Dollar per dollar, I believe that even if both drugs are successful my rights as a shareholder are safer when invested in Anavex and I have a greater chance of benefiting financially from the success of the company.
Beyond that, direct stimulation of synapse growth with a growth factor does not seem like a practical long term treatment. If I fertilize my plants too much they die. Maintenance of cellular homeostasis as in Anavex 2-73 seems like a more reasonable long term treatment goal. It is possible that the Neurotrope drug could be used to "jump start" severe cases but I do not see it as a widely used prophylactic drug which is likely for 2-73.
Recent TAOX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:01:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 09:21:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/02/2026 09:32:45 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/02/2026 09:30:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:23:07 PM
- TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation • PR Newswire (US) • 11/18/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/12/2025 09:10:46 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/07/2025 09:41:16 PM
- TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds • PR Newswire (US) • 11/04/2025 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/24/2025 08:12:47 PM
- TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency • PR Newswire (US) • 10/20/2025 01:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2025 09:13:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 10:12:21 AM
- TAO Synergies Announces $11 Million Private Placement • PR Newswire (US) • 10/13/2025 09:09:00 PM
- TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO) • PR Newswire (US) • 09/22/2025 01:15:00 PM
- TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event • PR Newswire (US) • 09/08/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2025 09:00:44 PM
- TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy • PR Newswire (US) • 08/26/2025 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2025 08:51:57 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/14/2025 08:50:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 08:19:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 09:17:38 PM

